文献速递心脑血管急症

STEMI直接PCI时省略阿司匹林

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.
PubMed 文献 · N Engl J Med · 2026-08-29
一句话结论STEMI直接PCI前启动低剂量普拉格雷单药治疗12个月,在全因死亡、卒中或心梗复合终点上不劣于阿司匹林联合低剂量普拉格雷DAPT的假设未成立,但大出血显著减少。

该多中心、开放标签、随机试验在日本纳入2216例接受直接PCI的STEMI患者,PCI前1:1随机分入低剂量普拉格雷单药组(1109例)或阿司匹林联合低剂量普拉格雷DAPT组(1107例),疗程12个月。主要终点为12个月全因死亡、卒中或心梗复合终点,预设非劣效界值为HR的95%CI上限1.50。结果显示单药组主要终点事件124例(KM估计11.0%),DAPT组94例(8.5%),HR 1.34(95%CI 1.02–1.75),非劣效性P=0.40,未达非劣效。大出血单药组61例(5.6%)低于DAPT组92例(8.4%),HR 0.66(95%CI 0.47–0.91)。

要点

  • STEMI直接PCI患者中,PCI前启动低剂量普拉格雷单药治疗12个月,主要复合终点(全因死亡、卒中或心梗)HR 1.34(95%CI 1.02–1.75),非劣效性未成立。
  • 单药组12个月主要终点KM估计11.0%,DAPT组8.5%,单药组事件数值更高。
  • 大出血(BARC 3或5型)单药组5.6%,DAPT组8.4%,HR 0.66(95%CI 0.47–0.91),单药组出血风险更低。
  • 明确的或可能的支架内血栓及严重不良事件在两组间似乎相似。
  • 该研究为开放标签设计,主要终点的非劣效假设未成立,不能据此在直接PCI的STEMI患者中常规省略阿司匹林。

适用人群与场景

  • 日本多中心纳入的接受直接PCI的STEMI患者,全分析人群2216例(单药组1109例,DAPT组1107例)。
  • 原文未提及具体纳入/排除标准及急诊/ICU/院前场景细节。

诊断标准与关键阈值

  • 主要终点为非劣效性检验,预设非劣效界值为主要终点HR的95%CI上限1.50。
  • 大出血定义为BARC 3型(非致命性大出血)或5型(致命性出血)。

处置流程与药物剂量

  • PCI前随机1:1分配至低剂量普拉格雷单药治疗或阿司匹林联合低剂量普拉格雷DAPT,疗程12个月。
  • 原文未提及具体药物剂量、给药途径、频次及目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 多中心、开放标签、随机试验,日本,全分析人群2216例(单药组1109例,DAPT组1107例),人群为接受直接PCI的STEMI患者。
  • 干预为PCI前启动低剂量普拉格雷单药治疗12个月,对照为阿司匹林联合低剂量普拉格雷DAPT 12个月。
  • 主要终点(12个月全因死亡、卒中或心梗复合终点):单药组124例(KM估计11.0%),DAPT组94例(KM估计8.5%),HR 1.34(95%CI 1.02–1.75),非劣效性P=0.40,未达非劣效。
  • 主要次要终点大出血(BARC 3或5型):单药组61例(KM估计5.6%),DAPT组92例(KM估计8.4%),HR 0.66(95%CI 0.47–0.91)。
  • 明确的或可能的支架内血栓及严重不良事件在两组间似乎相似。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照试验。
  • 局限:开放标签设计;主要终点非劣效性未成立;原文未提及其他局限。

对床旁实践的改变

  • 该结果不支持在直接PCI的STEMI患者中于PCI前常规省略阿司匹林、改用低剂量普拉格雷单药治疗,因为主要复合终点非劣效性未成立且单药组事件数值更高。
  • 单药组大出血更少,但这一获益需与主要终点未达非劣效及开放标签设计结合解读,不能据此改变默认DAPT策略。
  • 原文未提及适用/不适用人群的进一步限定及常见陷阱。

指南或共识出处

  • PREMIUM试验,ClinicalTrials.gov注册号NCT05709626,由Boston Scientific Japan资助;原文未提及指南或共识名称。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The safety of omitting up-front treatment with aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear.

METHODS: We conducted a multicenter, open-label, randomized trial in Japan involving patients with STEMI who were undergoing primary PCI. Patients were randomly assigned in a 1:1 ratio before PCI to receive low-dose prasugrel monotherapy or dual antiplatelet therapy (DAPT) with aspirin and low-dose prasugrel for 12 months. The primary outcome was a composite of death from any cause, stroke, or myocardial infarction at 12 months, which was assessed for noninferiority with a prespecified noninferiority margin of 1.50 for the 95% confidence interval of the hazard ratio. The major secondary outcome was major bleeding (defined as a bleeding event of Bleeding Academic Research Consortium [BARC] type 3 [nonfatal major bleeding] or 5 [fatal bleeding]) at 12 months, which was assessed for superiority if noninferiority was established for the primary outcome.

RESULTS: A total of 2216 patients were included in the full analysis population; 1109 were assigned to receive monotherapy and 1107 to receive DAPT. At 12 months, death from any cause, stroke, or myocardial infarction had occurred in 124 patients (Kaplan-Meier estimate, 11.0%) in the monotherapy group and in 94 patients (Kaplan-Meier estimate, 8.5%) in the DAPT group (hazard ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.75; P = 0.40 for noninferiority). Major bleeding had occurred in 61 patients (Kaplan-Meier estimate, 5.6%) in the monotherapy group and in 92 patients (Kaplan-Meier estimate, 8.4%) in the DAPT group (hazard ratio, 0.66; 95% CI, 0.47 to 0.91). The percentages of patients with definite or probable stent thrombosis and serious adverse events appeared to be similar in the two groups.

CONCLUSIONS: Among patients with STEMI who were undergoing primary PCI, low-dose prasugrel monotherapy initiated before PCI was not noninferior to DAPT for 12 months with respect to a composite of death from any cause, stroke, or myocardial infarction at 12 months. (Funded by Boston Scientific Japan; PREMIUM ClinicalTrials.gov number, NCT05709626.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Takahashi K, Kozuma K, Morino Y, et al. Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI. N Engl J Med. 2026. PMID: 42670955. doi:10.1056/NEJMoa2606997

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。